JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY)

Previous Articles     Next Articles

Intravitreal injection of Ranibizumab for idiopathic choroidal neovascularization lesion in two courses

ZI Yu-meng1, WANG Yu2, FAN Chuan-feng2, SHU Xiang-wen2, WU Chang-long2   

  1. 1. Weifang Medical College, Weifang 261031, Shandong, China; 2. Department of Ophthalmology, Jinan Second Peoples Hospital, Jinan 250001, Shandong, China
  • Received:2014-05-12 Online:2014-06-16 Published:2014-06-16

Abstract: Objective    To compare the effect of Ranibizumab by intravitreal injection for idiopathic choroidal neovascularization lesions (ICNV). Methods    By fundus fluorescein angiography (FFA), optical coherence tomography (OCT) examination and clinical manifestation diagnosis, 36 patients(36 cases) were diagnosed as idiopathic choroidal neovascular lesions, and based on the course they were divided into group A (duration <3 months ) and B (3 months ≤ duration <6 months) . All patients underwent routine intravitreal Ranibizumab injections. The BCVA (logMAR), refraction, intraocular pressure and dilated fundus investigation were determined.  Optical coherence tomography (OCT) was used to check the positional relationship between the lesion and the fovea and to measure CMT and FFA. Results    In comparison with before treatment, BCVA and CMT were significantly improved at 3 and 6 months after treatment (P<0.05). While on the 1, 3 and 6 months after treatment, BCVA and CMT showed no significant difference between the two groups  (P>0.05), but on 6 months, the injection time in group A (1.3±0.5 times) was lower than that in group B (2.1±1.2 times) (P<0.05). Conclusion    Intravitreal injection of Ranibizumab can quickly and effectively improve the patient condition. The earlier the treatment, the lower the injection time, the risk and the cost.

Key words: Idiopathic choroid neovascularization, Course, Ranibizumab

CLC Number: 

  • R773.4
[1] ZHOU Xueyi, LI Yiming, WANG Meiju, ZHANG Yuanyuan, ZHANG Lizhuo. The application of 25-gauge minimally invasive vitreoretinal surgery combined with intravitreal ranibizumab injections in the treatment of proliferative diabetic retinopathy. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 87-89.
[2] . Clinical observation on the treatment of CSME and NCSME by intravitreal injection of ranibizumab. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(2): 96-98.
[3] . Clinical observation on the treatment of BRVO-ME by the combination of laser therapy with Ranibizumab intravitreal injection. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(1): 110-113.
[4] MA Rongfeng, ZHU Fugao, SUN Meihong, FU Tao, ZHANG Xiaoheng, CAO Lin. Analysis on the relevant prognostic factors of sudden deafness and selection of course of treatment. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 69-74.
[5] ZHAO Lu, XIE Guoli, WANG Yanling. Changes of ocular hemodynamics after intravitreal ranibizumab injection in patients with wet age-related macular degeneration. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(4): 101-104.
[6] CHAI Xuerong, ZHANG Shixi, TAO Yu, SHEN Jiaquan. Effect of intravitreal ranibizumab injection combined with trabelectomy and panretinal photocoagulation for neovascular glaucoma [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(3): 72-75.
[7] LIU Yang-yun, JIANG Wen, MAO Kun-hua, CHEN Qiong. Application of hyperbaric oxygen therapy  on sudden deafness [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2012, 26(1): 70-72.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!